Modular Medical Announces Addition to the Russell Microcap(R) Index
Modular Medical Announces Addition to the Russell Microcap(R) Index
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.
醫療模塊化公司（Modular Medical，納斯達克：MODD），一個處於開發階段的胰島素輸送技術公司，旨在推出下一代用戶友好，價格實惠的胰島素泵技術。今天宣佈，它將在 2024 年 Russell 指數年度重新編制結束時成爲 Russell 微小市值指數的成員，並於 2024 年 7 月 1 日美國市場開盤時生效。
Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
成爲 Russell 微小市值指數成員，意味着一年內自動納入適當的成長風格指數和價值風格指數。FTSE Russell 主要根據客觀的市值排名和風格屬性確定其 Russell 指數的成員。
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Russell 指數被投資經理和機構投資者廣泛用於指數基金和作爲主動投資策略的基準。大約有 10.6 萬億美元的資產以 Russell 的美國指數爲基準。Russell 指數是全球領先的指數提供商 FTSE Russell 的一部分。
For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
有關 Russell 微小市值指數和 Russell 指數重新編制的更多信息，請訪問 FTSE Russell 網站上的“Russell Reconstitution”部分。
About Modular Medical
關於醫療模塊化公司
Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Our mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."
醫療模塊化公司（納斯達克：MODD）是一家處於開發階段的醫療器械公司，計劃推出下一代胰島素輸送技術。公司使用其專利技術，力求消除複雜性與功效之間的權衡，從而使高質量的胰島素輸送既負擔得起又容易學習。我們的使命是提高糖尿病患者獲得最高標準的血糖控制的機會，超越“超級用戶”，爲“我們其他人”的糖尿病護理提供支持。
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at
醫療模塊化公司由經驗豐富的醫療設備專業人士和微流控工程師保羅·迪佩納於成立。在創立醫療模塊化公司之前，迪佩納先生是 Tandem Diabetes 的創始人（2005 年），發明和設計了其 t：slim 胰島素泵。更多信息可在
All trademarks mentioned herein are the property of their respective owners.
這裏提到的所有商標均爲其各自所有者的財產。
CONTACT:
聯繫人：
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
Jeb Besser
首席執行官
醫療模塊化公司
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
來源：Modular Medical, Inc。